These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23722024)

  • 21. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of naturally occurring variation in the human papillomavirus 52 capsid proteins on recognition by type-specific neutralising antibodies.
    Godi A; Bissett SL; Masloh S; Fleury M; Li S; Zhao Q; Xia N; Cocuzza CE; Beddows S
    J Gen Virol; 2019 Feb; 100(2):237-245. PubMed ID: 30657447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.
    Combelas N; Saussereau E; Fleury MJ; Ribeiro T; Gaitan J; Duarte-Forero DF; Coursaget P; Touzé A
    J Transl Med; 2010 Mar; 8():28. PubMed ID: 20334659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.
    Karanam B; Gambhira R; Peng S; Jagu S; Kim DJ; Ketner GW; Stern PL; Adams RJ; Roden RB
    Vaccine; 2009 Feb; 27(7):1040-9. PubMed ID: 19095032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A protective and broadly cross-neutralizing epitope of human papillomavirus L2.
    Gambhira R; Karanam B; Jagu S; Roberts JN; Buck CB; Bossis I; Alphs H; Culp T; Christensen ND; Roden RB
    J Virol; 2007 Dec; 81(24):13927-31. PubMed ID: 17928339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serologic response to human papillomavirus genotypes following vaccination: findings from the HITCH cohort study.
    Morais S; Wissing MD; Khosrow-Khavar F; Burchell AN; Tellier PP; Coutlée F; Waterboer T; El-Zein M; Franco EL
    Infect Dis (Lond); 2024 Jan; 56(1):66-72. PubMed ID: 37994805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.
    Pastrana DV; Gambhira R; Buck CB; Pang YY; Thompson CD; Culp TD; Christensen ND; Lowy DR; Schiller JT; Roden RB
    Virology; 2005 Jul; 337(2):365-72. PubMed ID: 15885736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system.
    Touze A; El Mehdaoui S; Sizaret PY; Mougin C; Muñoz N; Coursaget P
    J Clin Microbiol; 1998 Jul; 36(7):2046-51. PubMed ID: 9650960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies.
    Bishop B; Dasgupta J; Klein M; Garcea RL; Christensen ND; Zhao R; Chen XS
    J Biol Chem; 2007 Oct; 282(43):31803-11. PubMed ID: 17804402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-risk human papillomavirus types in HIV-infected and HIV-uninfected young women in KwaZulu-Natal, South Africa: implications for vaccination.
    Mbatha JN; Taylor M; Kleppa E; Lillebo K; Galappaththi-Arachchige HN; Singh D; Kjetland EF; Baay MFD; Mkhize-Kwitshana ZL
    Infect Dis (Lond); 2017 Aug; 49(8):601-608. PubMed ID: 28403727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes.
    Mesher D; Soldan K; Lehtinen M; Beddows S; Brisson M; Brotherton JM; Chow EP; Cummings T; Drolet M; Fairley CK; Garland SM; Kahn JA; Kavanagh K; Markowitz L; Pollock KG; Söderlund-Strand A; Sonnenberg P; Tabrizi SN; Tanton C; Unger E; Thomas SL
    Emerg Infect Dis; 2016 Oct; 22(10):1732-40. PubMed ID: 27648688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.
    Bissett SL; Godi A; Fleury MJ; Touze A; Cocuzza C; Beddows S
    J Virol; 2015 Aug; 89(15):7748-57. PubMed ID: 25995264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
    Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
    PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity.
    Li Z; Song S; He M; Wang D; Shi J; Liu X; Li Y; Chi X; Wei S; Yang Y; Wang Z; Li J; Qian H; Yu H; Zheng Q; Yan X; Zhao Q; Zhang J; Gu Y; Li S; Xia N
    Nat Commun; 2018 Dec; 9(1):5360. PubMed ID: 30560935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches.
    Negahdaripour M; Eslami M; Nezafat N; Hajighahramani N; Ghoshoon MB; Shoolian E; Dehshahri A; Erfani N; Morowvat MH; Ghasemi Y
    Infect Genet Evol; 2017 Oct; 54():402-416. PubMed ID: 28780192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
    Kalnin K; Chivukula S; Tibbitts T; Yan Y; Stegalkina S; Shen L; Cieszynski J; Costa V; Sabharwal R; Anderson SF; Christensen N; Jagu S; Roden RBS; Kleanthous H
    Vaccine; 2017 Sep; 35(37):4942-4951. PubMed ID: 28778613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Synthesis of Main Capsid Protein of Anogenital Type HPV6 L1 in Plant Expression System on the Basis of Tomato Fruits.
    Rekoslavskaya NI; Salyaev RK; Stolbikov AS
    Dokl Biochem Biophys; 2021 May; 498(1):193-198. PubMed ID: 34189649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L1 and L2 gene polymorphisms in HPV-58 and HPV-33: implications for vaccine design and diagnosis.
    Chen Z; Jing Y; Wen Q; Ding X; Zhang S; Wang T; Zhang Y; Zhang J
    Virol J; 2016 Oct; 13(1):167. PubMed ID: 27717385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of an HPV vaccine for a broad spectrum of high-risk types.
    Kanda T; Kondo K
    Hum Vaccin; 2009; 5(1):43-5. PubMed ID: 18690012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.